Robert L. Copeland to Breast Neoplasms
This is a "connection" page, showing publications Robert L. Copeland has written about Breast Neoplasms.
Connection Strength
0.786
-
Copeland RL, Kanaan Y. New targets in triple-negative breast cancer. Nat Rev Cancer. 2021 12; 21(12):744.
Score: 0.327
-
Kanaan YM, Das JR, Bakare O, Enwerem NM, Berhe S, Beyene D, Williams V, Zhou Y, Copeland RL. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent. Anticancer Res. 2009 Jan; 29(1):191-9.
Score: 0.134
-
Dasi S, Naab TJ, Kwabi-Addo B, Apprey V, Beyene D, Dewitty RL, Nagel S, Williams R, Bolden K, Hayes-Dixon A, Shokrani B, Stewart DA, Kassim OO, Copeland RL, Kanaan YM. Methylation of ESRa Promoters in Benign Breast Tumors Could Be a Signature for Progression to Breast Cancer in African American Women. Cancer Genomics Proteomics. 2025 Mar-Apr; 22(2):208-230.
Score: 0.102
-
Aloufi A, Aubee J, Vargas KM, Apprey V, Thompson K, Copeland R, Kanaan Y, Ricks-Santi L, Brim H, Abbas M. Vitamin D receptor polymorphisms and associated miRNAs in the development of breast cancer in African American women. Gene. 2024 Nov 15; 927:148695.
Score: 0.098
-
Ren X, Ghassemi P, Kanaan YM, Naab T, Copeland RL, Dewitty RL, Kim I, Strobl JS, Agah M. Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification. ACS Sens. 2018 08 24; 3(8):1510-1521.
Score: 0.065
-
Owrang M, Copeland RL, Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL, Kanaan YM. Breast Cancer Prognosis for Young Patients. In Vivo. 2017 Jul-Aug; 31(4):661-668.
Score: 0.060